Skip to main content

Table 1 Comparison of baseline characteristics between medication groups

From: Defining phenotypes of long-term lithium and valproate response, including combination therapy: a modified application of the Alda scale in patients with bipolar disorders

Demographic and illness characteristics

Lithium, (n = 29)1

Valproate (n = 56)2

Combination, (n = 17)3

Group difference

Statistic

p-value

Sex [male, n (%)]

11 (37.9)

17 (30.4)

7 (41.2)

χ2 = 0.913

0.686

Age (current) [years, mean (SD)]

34.2 (9.2)

31.6 (8.65)

30.6 (8.3)

F = 1.113

0.332

Education [years, mean (SD)]

15.3 (2.3)

15.0 (2.0)

14.6 (1.7)

F = 0.617

0.542

Diagnosis [BD-I, n (%)]

28 (96.6)

44 (78.6)

15 (88.2)

FE

0.063

Age at onset [years, mean (SD)]

24.9 (9.3)

22.0 (7.1)

23.8 (8.4)

F = 1.362

0.261

Polarity at first episode [(hypo) manic, n (%)]

15 (51.7)

23 (41.1)

11 (48.0)

χ2 = 3.139

0.208

Pre-index-medication illness duration [years, mean (SD)]a

7.8 (5.8)

8.3 (6.6)

7.1 (4.5)

F = 0.239

0.788

Frequency of episodes [frequent, n (%)]

 Total episodes

6 (20.7)

14 (25.0)

4 (23.5)

χ2 = 0.197

0.906

 Major depressive episodes

5 (17.2)

10 (17.9)

4 (23.5)

χ2 = 0.328

0.849

 (Hypo)manic episodes

6 (20.7)

15 (26.8)

5 (29.4)

χ2 = 0.539

0.764

Family history of psychiatric disorders [present, n (%)]

18 (62.1)

34 (60.7)

9 (61.0)

χ2 = 0.414

0.813

Family history of mood disorders [present, n (%)]

12 (41.4)

21 (37.5)

6 (35.3)

χ2 = 0.196

0.906

Any anxiety disorder [present, n (%)]

5 (17.2)

13 (23.2)

1 (5.9)

χ2 = 2.636

0.268

Obsessive–compulsive disorder [present, n (%)]

5 (17.2)

10 (17.9)

1 (5.9)

FE

0.465

Seasonality [present, n (%)]

4 (13.8)

21 (21.4)

4 (23.5)

χ2 = 1.541

0.819

Rapid cycling [present, n (%)]

1 (3.4)

3 (5.4)

0 (0.0)

FE

1.000

Psychotic symptoms [present, n (%)]

26 (89.7)

41 (73.2)

13 (76.5)

χ2 = 3.099

0.212

Mixed episodes

8 (27.6)

13 (23.6)

3 (17.6)

χ2 = 0.585

0.746

Symptoms of (hypo)manic episodes

Present, n (%)

Present, n (%)

Present, n (%)

χ2

p-value

Elevated mood

25 (86.2)

39 (69.6)

14 (82.4)

3.306

0.192

Irritability

12 (41.4)

24 (42.9)

8 (47.1)

0.145

0.930

Grandiosity

23 (79.3)

36 (64.3)

11 (64.7)

2.149

0.341

Decreased sleep need

27 (93.1)

41 (73.2)

16 (94.1)

7.143

0.028b

Talkativeness

23 (79.3)

47 (83.9)

13 (76.5)

0.592

0.744

Flight of idea

24 (82.8)

39 (70.9)

12 (70.6)

1.539

0.463

Distractibility

27 (93.1)

44 (78.6)

15 (88.2)

FE

0.186

Hyperactivity

27 (93.1)

49 (87.5)

16 (94.1)

FE

0.732

Excessive involvement in activity

22 (75.9)

36 (64.3)

71 (69.6)

1.664

0.435

Delusion

20 (69.0)

28 (50.0)

12 (70.6)

4.003

0.135

Hallucination

6 (20.7)

16 (29.1)

6 (35.3)

1.254

0.534

Symptoms of depressive episodes

Present, n (%)

Present, n (%)

Present, n (%)

χ2

p-value

Depressed mood

24 (82.8)

45 (80.4)

10 (13.2)

4.116

0.128

Decreased interest

23 (79.3)

42 (75.0)

10 (58.8)

2.449

0.294

Appetite change

 No appetite change

13 (44.8)

25 (44.6)

9 (52.9)

0.387

0.824

 Decreased appetite

12 (41.4)

21 (37.5)

5 (29.4)

0.660

0.719

 Increased appetite

2 (6.9)

5 (8.9)

1 (5.9)

FE

1.000

Insomnia

19 (65.5)

40 (71.4)

7 (41.2)

5.238

0.073

Hypersomnia

8 (27.6)

16 (28.6)

3 (17.6)

0.826

0.662

Agitation

8 (27.6)

15 (26.8)

5 (29.4)

0.046

0.977

Retardation

12 (41.4)

22 (39.3)

3 (17.6)

3.098

0.212

Fatigue or loss of energy

23 (79.3)

40 (71.4)

10 (58.8)

2.212

0.331

Guilty feeling or worthlessness

17 (58.6)

28 (50.0)

50 (49.0)

3.707

0.157

Indecisiveness (concentration)

23 (79.3)

41 (73.2)

10 (58.8)

2.286

0.319

Suicidal ideation

15 (51.7)

31 (55.4)

8 (47.1)

0.385

0.825

Delusion

8 (27.6)

15 (26.8)

6 (35.3)

0.478

0.787

Hallucination

3 (10.3)

9 (16.1)

2 (11.8)

FE

0.923

  1. SD, standard deviation; BP-I, bipolar I disorder; FE, Fisher’s exact test
  2. aDuration from the illness onset to starting the index medications
  3. bSignificant difference in lithium vs. valproate group: p = 0.033; in valproate vs. combination group: p = 0.047; post-hoc analysis was conducted using Bonferroni’s method
  4. 1Lithium monotherapy group
  5. 2Valproate monotherapy group
  6. 3Lithium and valproate combination group